Journal of Neurology

, Volume 261, Issue 1, pp 98–105 | Cite as

Differential diagnoses to MS: experiences from an optic neuritis clinic

  • Henrik Horwitz
  • Tina Friis
  • Signe Modvig
  • Hanne Roed
  • Anna Tsakiri
  • Bjarne Laursen
  • Jette Lautrup Frederiksen
Original Communication
First Online:
Received:
Revised:
Accepted:

Abstract

Optic neuritis (ON) is closely linked to multiple sclerosis (MS). It may, however, also be associated to a range of autoimmune or infectious diseases. The purpose of this study was to assess the differential diagnoses in patients with suspected ON. In this retrospective study, we reviewed the files of all patients referred to the Clinic of Optic Neuritis, Glostrup Hospital, University of Copenhagen, Denmark, between January 2000 and November 2011. All patients were referred by ophthalmologists with possible ON. Patients diagnosed with MS prior to referral were excluded from the study. A total of 643 patients were included in the study. Apart from ON, the most frequent diagnoses were tumors (n = 15), ischemic or hypertensive neuropathies (n = 13), and retinal or choroid disorders (n = 9). Six patients were diagnosed with neuromyelitis optica. Rarer causes of visual loss were infections (n = 5), giant cell arteritis (n = 4), sarcoidosis (n = 3), thyrotoxicosis (n = 2), and hereditary or toxic neuropathies (n = 2). Nine percent of patients referred to the Clinic of Optic Neuritis had symptoms caused by medical, neurosurgical or ophthalmic disorders, and 0.9 % of our patients had NMO. Though most of these conditions are rare, it is of importance to keep them in mind upon encountering patients with symptoms of ON.

Keywords

Optic neuritis Differential diagnoses Neuromyelitis optica Multiple sclerosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Anja Francis Madsen, Ali Wafik Awade, Bente Fabild and Jytte Horne Pedersen are thanked for excellent technical assistance. This study was funded by: The A.P. Møller and Hustru Chastine Mc-Kinney Møller Foundation. Fabrikant Einar Willumsen Foundation. Aase og Ejnar Danielsen Foundation. The Danish Multiple Sclerosis Foundation.

Conflicts of interest

Henrik Horwitz: Nothing to disclose. Tina Friis: Nothing to disclose. Signe Modvig: Nothing to disclose. Hanne Roed: Nothing to disclose. Anna Tsakiri: Nothing to disclose. Bjarne Laursen: Nothing to disclose. Jette Lautrup Frederiksen has served on scientific advisory boards for and received funding for travel related to these activities and honoraria from Biogen Idec, Sanofi-Aventis, Genzyme, Teva, Novartis and Almirall. Jette Frederiksen has received speaker honoraria from Biogen Idec, Merck Serono and Teva. She has served as advisor on preclinical development for Takeda.

References

  1. 1.
    (2008) Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 65:727–732Google Scholar
  2. 2.
    Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76:1589–1595PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    di Bandettini PM, Primavera A, Capello E, Bandini F, Mazzarello G, Viscoli C, Schenone A (2010) A case of secondary syphilis presenting as optic neuritis. Neurol Sci 31:365–367CrossRefGoogle Scholar
  4. 4.
    Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581–588CrossRefPubMedGoogle Scholar
  5. 5.
    Blanc F, Ballonzoli L, Marcel C, De MS, Jaulhac B, De SJ (2010) Lyme optic neuritis. J Neurol Sci 295:117–119CrossRefPubMedGoogle Scholar
  6. 6.
    Constantino T, Digre K, Zimmerman P (2000) Neuro-ophthalmic complications of sarcoidosis. Semin Neurol 20:123–137CrossRefPubMedGoogle Scholar
  7. 7.
    Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water NJ, Robertson N (2012) The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 19:655–659CrossRefPubMedGoogle Scholar
  8. 8.
    Eggenberger ER (2001) Inflammatory optic neuropathies. Ophthalmol Clin North Am 14:73–82PubMedGoogle Scholar
  9. 9.
    Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, Asproudis I, Tsianos EV (2009) Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm Bowel Dis 15:29–34CrossRefPubMedGoogle Scholar
  10. 10.
    Francis DA, Compston DA, Batchelor JR, McDonald WI (1987) A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 50:758–765PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Frigui M, Frikha F, Sellemi D, Chouayakh F, Feki J, Bahloul Z (2011) Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. LupusGoogle Scholar
  12. 12.
    Gan JJ, Mandell AM, Otis JA, Holmuhamedova M, Perloff MD (2011) Suspecting optic neuritis, diagnosing Bartonella cat scratch disease. Arch Neurol 68:122–126CrossRefPubMedGoogle Scholar
  13. 13.
    Hickman SJ, Dalton CM, Miller DH, Plant GT (2002) Management of acute optic neuritis. Lancet 360:1953–1962CrossRefPubMedGoogle Scholar
  14. 14.
    http: www.who.int/classifications/icd/en/GRNBOOK.pdf (2013) The ICD-10 classification of mental and behavioural disorders
  15. 15.
    Hutchinson WM (1976) Acute optic neuritis and the prognosis for multiple sclerosis. J Neurol Neurosurg Psychiatry 39:283–289PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J NeurolGoogle Scholar
  17. 17.
    Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R, Franciotta D, Ruprecht K, Kuenz B, Rommer P, Kristoferitsch W, Wildemann B, Vincent A (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298:158–162CrossRefPubMedGoogle Scholar
  18. 18.
    Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56CrossRefPubMedGoogle Scholar
  19. 19.
    Kallenbach K, Frederiksen JL (2008) Unilateral optic neuritis as the presenting symptom of human immunodeficiency virus toxoplasmosis infection. Acta Ophthalmol 86:459–460CrossRefPubMedGoogle Scholar
  20. 20.
    Kerrison JB (2004) Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am 17:481–488CrossRefPubMedGoogle Scholar
  21. 21.
    Kim W, Lee JE, Li XF, Kim SH, Han BG, Lee BI, Kim JK, Choi K, Kim HJ (2012) Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 18:578–586CrossRefPubMedGoogle Scholar
  22. 22.
    Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMedGoogle Scholar
  23. 23.
    Massara A, Bonazza S, Castellino G, Caniatti L, Trotta F, Borrelli M, Feggi L, Govoni M (2010) Central nervous system involvement in Sjogren’s syndrome: unusual, but not unremarkable—clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford) 49:1540–1549CrossRefGoogle Scholar
  24. 24.
    Orssaud C, Roche O, Dufier JL (2007) Nutritional optic neuropathies. J Neurol Sci 262:158–164CrossRefPubMedGoogle Scholar
  25. 25.
    Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, Franciotta D, Bergamaschi R, Littleton E, Palace J, Seelig HP, Hohlfeld R, Vincent A, Zipp F (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Purvin V, Sundaram S, Kawasaki A (2011) Neuroretinitis: review of the literature and new observations. J Neuroophthalmol 31:58–68CrossRefPubMedGoogle Scholar
  27. 27.
    Rizzo JF III, Lessell S (1991) Optic neuritis and ischemic optic neuropathy. Overlapping clinical profiles. Arch Ophthalmol 109:1668–1672PubMedGoogle Scholar
  28. 28.
    Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250CrossRefPubMedGoogle Scholar
  29. 29.
    Rolak LA, Fleming JO (2007) The differential diagnosis of multiple sclerosis. Neurologist 13:57–72CrossRefPubMedGoogle Scholar
  30. 30.
    Rucker JC, Biousse V, Newman NJ (2004) Ischemic optic neuropathies. Curr Opin Neurol 17:27–35CrossRefPubMedGoogle Scholar
  31. 31.
    Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP (1990) A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol 27:386–393CrossRefPubMedGoogle Scholar
  32. 32.
    Siuko M, Tienari PJ, Saastamoinen KP, Atula S, Miettinen A, Kivela T, Setala K (2013) Neuromyelitis optica and aquaporin-4 (AQP4) autoantibodies in consecutive optic neuritis patients in Southern Finland. Acta OphthalmolGoogle Scholar
  33. 33.
    Soderstrom M, Ya-Ping J, Hillert J, Link H (1998) Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 50:708–714CrossRefPubMedGoogle Scholar
  34. 34.
    Waters P, Vincent A (2008) Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 15:99–105PubMedGoogle Scholar
  35. 35.
    Wilhelm H, Peters T, Ludtke H, Wilhelm B (2007) The prevalence of relative afferent pupillary defects in normal subjects. J Neuroophthalmol 27:263–267CrossRefPubMedGoogle Scholar
  36. 36.
    Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114CrossRefPubMedGoogle Scholar
  37. 37.
    Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815CrossRefPubMedGoogle Scholar
  38. 38.
    Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefPubMedGoogle Scholar
  39. 39.
    www.medstat.dk (2012) Statens Serum Institut
  40. 40.
    Yu-Wai-Man P, Griffiths PG, Chinnery PF (2011) Mitochondrial optic neuropathies—disease mechanisms and therapeutic strategies. Prog Retin Eye Res 30:81–114PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Henrik Horwitz
    • 1
    • 2
  • Tina Friis
    • 3
  • Signe Modvig
    • 1
  • Hanne Roed
    • 4
  • Anna Tsakiri
    • 5
  • Bjarne Laursen
    • 6
  • Jette Lautrup Frederiksen
    • 5
  1. 1.Clinic of Optic Neuritis, Glostrup HospitalUniversity of CopenhagenCopenhagenDenmark
  2. 2.FrederiksbergDenmark
  3. 3.Department of Clinical Biochemistry, Immunology and GeneticsStatens Serum InstitutCopenhagenDenmark
  4. 4.Department of OphthalmologyNæstved SygehusNaestvedDenmark
  5. 5.Department of Neurology, Glostrup HospitalUniversity of CopenhagenCopenhagenDenmark
  6. 6.Statens Institut for FolkesundhedUniversity of Southern DenmarkOdenseDenmark

Personalised recommendations